ArticleBlood2018
Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Outline of Iron Metabolism, with Emphasis on Erythroid Cells.Mediterranean journal of hematology and infectious diseases · 2025Review
- Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice.eLife · 2023Article
- Novel potential therapeutics to modify iron metabolism and red cell synthesis in diseases associated with defective erythropoiesis.Haematologica · 2023Review
- Flavor of Iron at EHA2023: Novel Regulatory Mechanisms and Therapeutic Options for the Correction of Anemia.HemaSphere · 2023Article
- Targeting the Second Transferrin Receptor as Emerging Therapeutic Option for β-Thalassemia Major.HemaSphere · 2022Article
- Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia.American journal of hematology · 2022Article
- Does Hepcidin Tuning Have a Role among Emerging Treatments for Thalassemia?Journal of clinical medicine · 2022Review
- The mutual crosstalk between iron and erythropoiesis.International journal of hematology · 2022Review
- Iron-Deficiency in Atopic Diseases: Innate Immune Priming by Allergens and Siderophores.Frontiers in allergy · 2022Review
- Effect of Erythropoietin on the Expression of Murine Transferrin Receptor 2.International journal of molecular sciences · 2021Article
- Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs.International journal of molecular sciences · 2021Review
- The EHA Research Roadmap: Anemias.HemaSphere · 2021Article
- Transferrin Receptors in Erythropoiesis.International journal of molecular sciences · 2020Review
- The VP1u of Human Parvovirus B19: A Multifunctional Capsid Protein with Biotechnological Applications.Viruses · 2020Review
- Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.Blood · 2020Article
- Iron metabolism and iron disorders revisited in the hepcidin era.Haematologica · 2020Review
- Lobe specificity of iron binding to transferrin modulates murine erythropoiesis and iron homeostasis.Blood · 2019Article
- Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis.eLife · 2019Article
- Effect of stimulated erythropoiesis on liver SMAD signaling pathway in iron-overloaded and iron-deficient mice.PloS one · 2019Article
- Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-thalassemias are genetic disorders characterized by anemia, ineffective erythropoiesis, and iron overload. Current treatment of severe cases is based on blood transfusion and iron chelation or allogeneic bone marrow (BM) transplantation. Novel approaches are explored for nontransfusion-dependent patients (thalassemia intermedia) who develop anemia and iron overload. Here, we investigated the erythropoietin (EPO) receptor partner, transferrin receptor 2 (TFR2), as a novel potential therapeutic target. We generated a murine model of thalassemia intermedia specifically lacking BM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.